Kararlı angina pektoris

Year 2012, , 117 - 121, 06.02.2013

Korhan Soylu

https://doi.org/10.5835/jecm.omu.29.s3.004

Abstract

Koroner arter hastalığı tüm dünyada yaygın bir ölüm nedenidir. Kararlı angina pektoris göğüste veya çevresinde efor ile oluşan bir rahatsızlıktır. Bu derleme kronik stabil anjinanın medikal ve invasif tedavi seçeneklerini ve yeni stratejileri ortaya koymayı amaçlamıştır. Tedavinin amacı yaşam kalitesini iyileştirmek, kardiyovasküler olay ve ölümleri azaltmaktır. İdeal tedavi seçiminin belirlenebilmesi için risk derecelendirmesi yapılması gerekir. Bu derecelendirme hiyerarşisi: Klinik değerlendirme, stres testleri, sol ventrikül fonksiyonu ve koroner anjiyografi şeklinde sıralanabilir.

Keywords

Kararlı angina, Angina, Göğüs ağrısı, Koroner arter hastalığı, Efor anginası

References

• Antithrombotic Trialists’ Collaboration, 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. B.M.J. 324, 71-86.
• Califf, R.M., Mark, D.B., Harrell, F.E., Jr Hlatky, M.A., Lee, K.L., Rosati, R.A., Pryor, D.B., 1988. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J. Am. Coll. Cardiol. 11, 20-26.
• C.A.P.R.I.E. Steering Committee, 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (C.A.P.R.I.E.). Lancet. 348, 1329-1339.
• Cox, J., Naylor, C.D., 1992. The Canadian Cardiovascular Society grading scale for angina pectoris: Is it time for refinements. Ann. Intern. Med. 117, 677-683.
• Diamond, A.G., 1983. A clinically relevant classification of chest discomfort. J. Am. Coll. Cardiol. 1, 574–575.
• Emond, M., Mock, M.B., Davis, K.B., Fisher, L.D., Holmes, D.R., Jr Chaitman, B.R., Kaiser, G.C., Alderman, E., Killip, T., 1994. III. Long-term survival of medically treated patients in the coronary artery surgery study (C.A.S.S.) registry. Circulation. 90, 2645-2657.
• ESC/EAS Guidelines for the management of dyslipidaemias, 2011. Eur. Heart J. 32, 1769–1818.
• European Society of Cardiology, 2006. Guidelines on the management of stable angina pectoris. Eur. Heart J. 27, 1341-1381.
• European Society of Cardiology and the European Association for Cardio-Thoracic Surgery Guidelines on myocardial revascularization, 2010. Eur. Heart J. 31, 2501-2555.
• European Society of Hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. Eur. Heart J. 28, 1462-1536.
• Fox, K., Ford, I., Steg, P.G., Tendera, M., Robertson, M., Ferrari, R., 2009. Beautiful investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled beautiful trial. Eur. Heart J. 30, 2337-2345.
• Fox, M.K., 2003. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 362, 782-788.
• Fu, L.W., Longhurst, J.C., 2005. Interactions between histamine and bradykinin in stimulation of ischaemically sensitive cardiac afferents in felines. J. Physiol. 565, 1007.
• Hultgren, H.N., Peduzzi, P., 1984. Relation of severity of symptoms to prognosis in stable angina pectoris. Am. J. Cardiol. 54, 988-993.
• Mark, D.B., Hlatky, M.A., Harrell, F.E., Jr Lee, K.L., Califf, R.M., Pryor, D.B., 1987. Exercise treadmill score for predicting prognosis in coro- nary artery disease. Ann. Intern. Med. 106, 793-800.
• Marzilli, M., Klein, W.W., 2003. Efficacy and tolerability of trimetazidine in stable angina: A meta-analysis of randomized, double-blind, con- trolled trials. Coron. Artery Dis. 14, 171–179.
• Nissen, S.E., Tuzcu, E.M., Libby, P., Thompson, P.D., Ghali, M., Garza, D., Berman, L., Shi, H., Buebendorf, E., Topol, E.J., 2004. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The camelot study: A randomized controlled trial. JAMA. 292, 2217-2225.
• Onat, A., Şurdum-Avcı, G., Şenocak, M., Örnek, E.,Gözükara, Y., Karaaslan, Y., Özışık, U., İşler, M., Tabak, F., Özcan, R., 1991. Türkiye'de erişkinlerde kalp hastalığı ve risk faktörleri sıklığı taraması: 3. Kalp hastalıkları prevalansı. Türk Kardiyol. Dern. Arş. 19, 26-33.
• Raab, W., 1962. The sympathogenic biochemical trigger mechanism of angina pectoris: Its therapeutic suppression and long-term prevention. Am. J. Cardiol. 9, 576-590.
• The Danish verapamil infarction trial II–DAVIT II, 1990. Effect of verapamil on mortality and major events after acute myocardial infarction. Am. J. Cardiol. 66, 779-785.
• The multicenter diltiazem postinfarction trial research group-MDPIT. 1988. The effect of diltiazem on mortality and reinfarction after myocar- dial infarction. N. Engl. J. Med. 319, 385-392.
• Werdan, K., Ebelt, H., Nuding, S., Höpfner, F., Hack, G., Müller-Werdan, U., 2012. Ivabradine in combination with beta-blocker improve symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study. Clin. Res. Cardiol. 101, 365-373.
• Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 342, 145-153.